Crossmark

N,N-dimethylacetamide blocks inflammation-induced preterm birth and remediates maternal systemic immune responses

Published Online: 2025-03-10

Authors

Reznik, Sandra E.

Kashou, Alexander

Ward, Daylan

Yellon, Steven M.
License Information

Text and Data Mining valid from 2025-03-10

Version of Record valid from 2025-03-10
More Information

Article History

Received: 15 July 2024

Accepted: 4 March 2025

First Online: 10 March 2025

Declarations

:

: SER holds a patent for the administration of DMA for the treatment of preterm birth (11,717,499).

Document is current